GERO is a cutting-edge biotechnology company dedicated to the mission of curing age-related human diseases and understanding, slowing, and even halting the aging process itself.
Gero's goal is to extend healthy lifespan dramatically and delay age-related health issues.
Gero was founded in Singapore in 2015 by Peter Fedichev. The company is headquartered in Palo Alto, CA and Singapore.
Gero is at the forefront of a growing field of medical research that suggests that aging is not an inevitable part of human existence but rather a treatable condition that can be manipulated, slowed, or even stopped using modern technology. Gero uses cutting-edge generative AI tools to analyze real-world longitudinal human health data.
Gero has developed proprietary, physics-guided machine-learning frameworks to explore human biology in a bias-free way. Gero’s approach allows separating the effects of aging from the effects of diseases enabling human genetics-driven target discovery for chronic and age-related diseases.
Gero’s large health models (LHMs) are generative, predictive models of human health. Gero announced a research collaboration with Pfizer and is in discussions with other pharmaceutical companies that are evaluating age-related diseases as a growing market.
Gero is backed by Bulba Ventures, Melnichek Investments, VitaDAO, Fintech Lab, Slush Singapore X Philips Startup Challenge, and others. The company closed $6M in a Series A extension round on Oct 18, 2023. This brings Gero's total funding to $13.5M to date.